Biopharma Business Check – Financing and Review (Pharmaceutical Executive, February 2025)Jonathan Choi2025-02-17T18:02:53+00:00February 7th, 2025|Featured, Our Publications|
Global M&A Treads WaterJonathan Choi2025-02-17T17:56:46+00:00February 7th, 2025|Featured, Our Publications|
Divestitures in the Current EnvironmentJonathan Choi2025-02-05T22:23:10+00:00January 28th, 2025|Featured, Our Publications|
Reflections on 2024 and Outlook – Stock Market and FundingJonathan Choi2025-02-05T22:13:34+00:00January 28th, 2025|Featured, Our Publications|
Reflections on 2024 and Outlook – Senior Management Approach to M&AJonathan Choi2025-02-05T22:09:34+00:00January 28th, 2025|Featured, Our Publications|
Reflections on 2024 and Outlook – Biotech and Pharma M&AJonathan Choi2025-02-05T22:03:00+00:00January 28th, 2025|Featured, Our Publications|
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)Jonathan Choi2024-11-06T21:10:32+00:00October 24th, 2024|Featured, Our Publications|
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading? (Pharmaceutical Executive)Jonathan Choi2024-11-06T21:10:53+00:00October 23rd, 2024|Featured, Our Publications|
Industry Restructuring & Inorganic Growth Through an Era of Chronic Oversupply (World Chemical Forum Speech September 10, 2024)Jonathan Choi2024-10-14T18:41:13+00:00September 10th, 2024|Featured, Our Publications|
Chemical Debt Financing Rebounds (ICIS Chemical Business September 6 – September 12, 2024)Jonathan Choi2024-10-15T15:22:50+00:00September 6th, 2024|Featured, Our Publications|
